Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248118 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00248118: Clinical Trial Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00248118 is a Phase 2 study that was terminated before completion, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00248118, a Phase 2 study, was terminated before completion, sponsored by National Institute on Drug Abuse (NIDA).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to determine: 1) the short-term clinical efficacy and safety of bupropion for helping adolescent tobacco smokers quit, and 2) The role of withdrawal symptoms in the maintenance of smoking in adolescents.
Interventions
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Why NCT00248118 stopped before completion
NCT00248118 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 1 intervention - of which Bupropion is the first listed.
NCT00248118 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00248118 about?
NCT00248118 is a clinical study titled "Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking". The purpose of this study is to determine: 1) the short-term clinical efficacy and safety of bupropion for helping adolescent tobacco smokers quit, and 2) The role of withdrawal symptoms in the maintenance of smoking in adolescents.
What is the current status of trial NCT00248118?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2005-01. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00248118?
The interventions under investigation include: Bupropion (DRUG).
Who is sponsoring clinical trial NCT00248118?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00248118's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia